Kobori Hiroyuki, Prieto-Carrasquero Minolfa C, Ozawa Yuri, Navar L Gabriel
Department of Physiology and Hypertension and Renal Center of Excellence, Tulane University Health Sciences Center, 1430 Tulane Avenue, #SL39, New Orleans, LA 70112-2699, USA.
Hypertension. 2004 May;43(5):1126-32. doi: 10.1161/01.HYP.0000122875.91100.28. Epub 2004 Mar 22.
Angiotensin (Ang) II-infused hypertensive rats exhibit increases in renal angiotensinogen mRNA and protein, as well as urinary angiotensinogen excretion in association with increased intrarenal Ang II content. The present study was performed to determine if the augmentation of intrarenal angiotensinogen requires activation of Ang II type 1 (AT1) receptors. Male Sprague-Dawley rats (200 to 220 g) were divided into 3 groups: sham surgery (n=10), subcutaneous infusion of Ang II (80 ng/min, n=11), and Ang II infusion plus AT1 blocker (ARB), olmesartan (5 mg/d, n=12). Ang II infusion progressively increased systolic blood pressure (SBP) compared with sham (178+/-8 mm Hg versus 119+/-4 at day 11). ARB treatment prevented hypertension (113+/-6 at day 11). Twenty-four-hour urine collections were taken at day 12, and plasma and tissue samples were harvested at day 13. The Ang II+ARB group had a significant increase in plasma Ang II compared with Ang II and sham groups (365+/-46 fmol/mL versus 76+/-9 and 45+/-14, respectively). Nevertheless, ARB treatment markedly limited the enhancement of kidney Ang II by Ang II infusion (65+/-17 fmol/g in sham, 606+/-147 in Ang II group, and 288+/-28 in Ang II+ARB group). Ang II infusion significantly increased kidney angiotensinogen compared with sham (1.69+/-0.21 densitometric units versus 1.00+/-0.17). This change was reflected by increased angiotensinogen immunostaining in proximal tubules. ARB treatment prevented this increase (1.14+/-0.12). Urinary angiotensinogen excretion rates were enhanced 4.7x in Ang II group (4.67+/-0.41 densitometric units versus 1.00+/-0.21) but ARB treatment prevented the augmentation of urinary angiotensinogen (0.96+/-0.23). These data demonstrate that augmentation of intrarenal angiotensinogen in Ang II-infused rats is AT1-dependent and provide further evidence that urinary angiotensinogen is closely linked to intrarenal Ang II in Ang II-dependent hypertension.
输注血管紧张素(Ang)II的高血压大鼠肾血管紧张素原mRNA和蛋白增加,尿血管紧张素原排泄也增加,同时肾内Ang II含量升高。本研究旨在确定肾内血管紧张素原的增加是否需要激活血管紧张素II 1型(AT1)受体。雄性Sprague-Dawley大鼠(200至220克)分为3组:假手术组(n = 10)、皮下输注Ang II组(80 ng/分钟,n = 11)和Ang II输注加AT1阻滞剂(ARB)奥美沙坦组(5毫克/天,n = 12)。与假手术组相比,输注Ang II使收缩压(SBP)逐渐升高(第11天时为178±8毫米汞柱,而假手术组为119±4)。ARB治疗可预防高血压(第11天时为113±6)。在第12天收集24小时尿液,在第13天采集血浆和组织样本。与Ang II组和假手术组相比,Ang II + ARB组血浆Ang II显著增加(分别为365±46 fmol/mL、76±9和45±14)。然而,ARB治疗显著限制了Ang II输注导致的肾Ang II增加(假手术组为65±17 fmol/g,Ang II组为606±147,Ang II + ARB组为288±28)。与假手术组相比,Ang II输注显著增加了肾血管紧张素原(光密度单位为1.69±0.21,而假手术组为1.00±0.17)。近端小管中血管紧张素原免疫染色增加反映了这种变化。ARB治疗可预防这种增加(1.14±0.12)。Ang II组尿血管紧张素原排泄率提高了4.7倍(光密度单位为4.67±0.41,而假手术组为1.00±0.21),但ARB治疗可预防尿血管紧张素原的增加(0.96±0.23)。这些数据表明,输注Ang II的大鼠肾内血管紧张素原的增加是AT1依赖性的,并进一步证明在Ang II依赖性高血压中,尿血管紧张素原与肾内Ang II密切相关。